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Flow cytometric immunobead assay for fast and easy detection
of PML–RARA fusion proteins for the diagnosis of
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EHA Dekking1,2, VHJ van der Velden1, R Varro3, H Wai3, S Bo¨ttcher4, M Kneba4, E Sonneveld5, A Koning5, N Boeckx6, N Van Poecke6,
P Lucio7, A Mendonc¸a7, L Sedek8, T Szczepan´ski8, T Kalina9, V Kanderova´9, P Hoogeveen1, J Flores-Montero10, MC Chillo´n10, A Orfao10,
J Almeida10, P Evans11, M Cullen11, AL Noordijk1,2, PM Vermeulen1,2, MT de Man1,2, EP Dixon12, WM Comans-Bitter1 and JJM van Dongen1
on behalf of the EuroFlow Consortium (EU-FP6, LSHB-CT-2006-018708)
The PML–RARA fusion protein is found in approximately 97% of patients with acute promyelocytic leukemia (APL). APL can be
associated with life-threatening bleeding complications when undiagnosed and not treated expeditiously. The PML–RARA fusion
protein arrests maturation of myeloid cells at the promyelocytic stage, leading to the accumulation of neoplastic promyelocytes.
Complete remission can be obtained by treatment with all-trans-retinoic acid (ATRA) in combination with chemotherapy. Diagnosis
of APL is based on the detection of t(15;17) by karyotyping, ﬂuorescence in situ hybridization or PCR. These techniques are laborious
and demand specialized laboratories. We developed a fast (performed within 4–5 h) and sensitive (detection of at least 10%
malignant cells in normal background) ﬂow cytometric immunobead assay for the detection of PML–RARA fusion proteins in cell
lysates using a bead-bound anti-RARA capture antibody and a phycoerythrin-conjugated anti-PML detection antibody. Testing of
163 newly diagnosed patients (including 46 APL cases) with the PML–RARA immunobead assay showed full concordance with the
PML–RARA PCR results. As the applied antibodies recognize outer domains of the fusion protein, the assay appeared to work
independently of the PML gene break point region. Importantly, the assay can be used in parallel with routine immunophenotyping
for fast and easy diagnosis of APL.
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INTRODUCTION
The presence of t(15;17) with the PML–RARA fusion gene is
considered to be the hallmark of acute promyelocytic leukemia
(APL), also known as acute myeloid leukemia (AML) type M3.1
Initially t(15;17) was assumed to be present in all APL patients.
However, over the last 10 years a sizeable minority of APL cases
(B5%) has been identiﬁed as lacking this classical translocation,
but containing the PML–RARA fusion gene. Such nonclassical PML–
RARA fusion genes can be caused by chromosomal aberrations,
such as insertions or complex chromosomal aberrations, which
may be missed by cytogenetics and ﬂuorescence in situ
hybridization (FISH), but are detected by PCR.2–4
The break points in the RARA gene are all located in intron 2
(B15 kb), whereas the vast majority of break points in the PML
gene cluster in the break point cluster region (bcr) of intron 6
(bcr1;B55% of cases), exon 6 (bcr2; B5% of cases) or intron 3
(bcr3; B40% of cases).3 Two APL cases with t(15;17) have been
reported with breaks in PML exon 7 (Figure 1).5 A rare subgroup of
APL cases (2–3%) has variant RARA gene translocations with a non-
PML fusion partner. So far seven alternative RARA gene partners
have been identiﬁed in APL cases: PLZF, NPM, NUMA, STAT5B,
FIP1L1, PRKAR1A and BCOR.6–14 The PLZF gene appears to be the
most frequent alternative partner and is present inB1% of all APL
cases (Table 1).7,10
Finally, inB1% of APL molecular techniques have not identiﬁed
a RARA gene rearrangement.2 Further studies are needed to assess
what genetic event causes APL characteristics in these patients. In
some of these cases the PCR technique may have given false-
negative results due to unusual positioning of the PML or RARA
gene break points, not covered by the applied primers.5
APL patients with the PML–RARA fusion gene aberration have
been shown to be highly sensitive to retinoid differentiating
agents, such as all-trans-retinoic acid (ATRA). Combination therapy
(ATRA and chemotherapy) has signiﬁcantly improved treatment
outcome in APL patients. The long-term outcome is now favorable
because of the low risk of relapse and prevention of life-
threatening coagulopathy at diagnosis. Also in recent years,
As2O3 was introduced as a new and efﬁcient treatment alternative
for APL patients. Consequently, stem cell transplantation in ﬁrst
remission is no longer recommended.15,16
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It should be noted that APL patients with the most frequent
variant fusion gene, the PLZF-RARA fusion gene (Table 1), are not
sensitive to ATRA treatment.10,16,17 However, other rare variant APL
cases with NPM-RARA and NUMA-RARA fusion genes are sensitive to
ATRA treatment, comparable to PML–RARA positive cases.11
As the ﬁrst description of APL, life-threatening bleeding
problems have been identiﬁed as the most notorious manifesta-
tion of the disease. This coagulopathy in many APL patients leads
to pulmonary and cerebral hemorrhages, if the appropriate
treatment regimen is not initiated instantly.15,16,18 Even upon
treatment, APL-related coagulopathy takes 5–8 days to improve.
Many hematologists consider the correct diagnosis in a patient
with APL a medical emergency, because of the coagulopathy
manifestations, which continue to be a major cause of death in
APL patients. Consequently, a positive diagnosis of APL is of
utmost importance for patient care in leukemia treatment. Such
diagnosis preferably should be provided within hours and not
within days.
Although the clinical and cytomorphological picture of APL seems
relatively clear, the leukemic cells in a subset of patients (5–10%)
do not exhibit the typical APL morphology.19 Consequently, it is
strongly recommended to make a fast and accurate diagnosis of
the PML–RARA aberration. Because of the risk of early death due to
bleeding, best clinical practice recommends that APL should be
excluded in each patient with newly diagnosed AML.15,16
At present, the diagnosis of PML–RARA positive APL cases is
based on the result of cytomorphology and immunophenotyping
combined with karyotyping, FISH, and/or PCR. Immunophenotyp-
ing results are typically completed on the same day, but the other
techniques are time consuming (usually 1–2 days for FISH and PCR
techniques and 1–2 weeks for karyotyping) and are restricted to
specialized laboratories with well-trained personnel. In addition
some laboratories use the anti-PML protein immunoﬂuorescence
test, which is claimed to result in a macrogranular nuclear staining
pattern in case of a wild-type (nontranslocated) PML gene, but
gives multiple smaller dots in case of a PML–RARA fusion
gene.15,20,21 This assay is fast, but requires sufﬁcient ﬂuorescence
microscopy experience for reliable reading and false-negativity
cannot be excluded.20,21
Therefore, novel methods are needed for fast and easy
diagnosis of PML–RARA positive APL, without subjective inter-
pretation steps. We have developed a new antibody-based ﬂow
cytometric immunobead assay for speciﬁc detection of the PML–
RARA fusion protein, comparable to our BCR-ABL immunobead
assay.22 To allow detection of all known PML–RARA fusion
proteins independent of the break point (bcr1, bcr2, bcr3, and
the rare bcr in exon 7), antibodies were generated that recog-
nize immunogenic epitopes located upstream of the bcr’s
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Figure 1. Structure of the PML and RARA genes with the break point regions and the corresponding fusion gene transcripts. (a) The PML gene
contains three well-defined small break point cluster regions (bcr’s): bcr1 in intron 6, bcr2 in the downstream part of exon 6 and bcr3 in
intron 3. In addition two rare break points in intron 7 have been reported. In the RARA gene the break points cluster in intron 2 (B15 kb).
(b) The three well-defined bcr’s and the rare intron 7 breaks in the PML gene result in four different PML–RARA fusion transcripts. Percentages
refer to the relative frequency of the various PML–RARA variants.
Table 1. RARA fusion genes in APL
Chromosome aberration Fusion gene Relative
frequency
in APL
t(15;17) (q24;q21) (classical) PML–RARA B92%
Other 15q24 and 17q21 aberrationsa PML–RARAa B5%
t(11;17) (q23;q21) PLZF-RARA B1%
t(5;17) (q35;q21) NPM-RARA B0.5%
t(11;17) (q13;q21) NUMA-RARA Rare
Der(17) STAT5B-RARA Rare
t(4:17) (q12;q21) FIP1L1-RARA Two cases
Complex der(17) PRKAR1A-RARA Single case
t(x;17) (p11;q21) BCOR-RARA Single case
No aberration detectable No RARA gene
rearrangement
B1%
Abbreviation: APL, acute promyelocytic leukemia. aThe nonclassical 15q24
and 17q21 aberrations with PML–RARA fusion genes can be caused by
several types of genetic aberrations, such as insertions and complex
translocations.2–4
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(upstream of bcr3) for PML and downstream of the break point
region in intron 2 known for RARA. The antibodies were combined
into a prototype immunobead assay in which the anti-RARA
antibody was used as a capture antibody and the anti-PML
antibody as a phycoerythrin (PE)-conjugated detection antibody.
After initial testing on cell lines and a small series of patient
samples, the EuroFlow Consortium (EU-FP6, LSHB-CT-2006-
018708) evaluated 163 acute leukemias at diagnosis, which
showed full concordance between PCR and immunobead results.
MATERIALS AND METHODS
Cell lines
Several leukemic cell lines were used to investigate the speciﬁcity of the
PML–RARA immunobead assay. The NB4 cell line with t(15;17) and PML–
RARA transcripts was used as positive control; the PML break point in this
cell line is located in bcr1 (intron 6).23 Several other leukemic cell lines were
used as negative controls: ME-1 with inv(16) and CBFB-MYH11 transcripts,
MV4-11 with t(4;11) and MLL-AF4 transcripts, K562 with t(9;22) and BCR-ABL
transcripts, 697 with t(1;19) and E2A-PBX1 transcripts, RCH-ACV with t(1;19)
and E2A-PBX1 transcripts, KASUMI-1 with t(8;21) and AML1-ETO transcripts,
and REH with t(12;21) and TEL-AML1 transcripts.3 All leukemic cell
lines used in this study are available from the German Collection of
Microorganisms and Cell cultures (DSMZ GmbH, Braunschweig, Germany).
Healthy controls
Peripheral blood (PB) samples were obtained from healthy donors after
informed consent according to the local Medical Ethics Committee
guidelines. Total white blood cells (WBC) were obtained by NH4Cl lysis of
the erythrocytes. PB mononuclear cells (PBMC) were obtained by ﬁcoll
separation. To mimic leukemic samples with varying tumor loads, cells of
the PML–RARA expressing cell line NB4 were mixed at different concen-
trations in either PML–RARA negative cell lines or in normal PBMC or WBC.
Patient samples
Freshly collected or frozen bone marrow (BM) or PB samples were
obtained from patients in accordance with the Declaration of Helsinki. All
participants in the EuroFlow Consortium (EU-FP6 grant LSHB-CT-2006-
018708) obtained approval from the local Medical Ethics Committee for
secondary use of remaining diagnostic material of patients suspected to
have a hematological malignancy. Cell samples were processed by either
NH4Cl lysis or ﬁcoll separation.
Antibodies for speciﬁc detection of PML and RARA domains
Antibodies were raised against recombinantly expressed epitopes of PML
and RARA domains that are present in all known fusion protein variants,
which result from various break point regions. The ﬁrst PML domain (ﬁrst
46 amino acids) located before the ﬁrst Zinc ﬁnger domain was used for
immunization (Figure 2a). For the generation of anti-RARA antibodies, the
C-terminal domain of RARA (last 70 amino acids) was recombinantly
expressed and used for immunization (Figure 2b).
The recombinant proteins were expressed in HEK 293FS cells and after
puriﬁcation were used for immunization of SJL (anti-PML) or Balb/c (anti-
RARA) mice using subcutaneous immunization techniques optimized at BD
Diagnostics (Durham, NC, USA), followed by fusion of spleen cells with the
P3X,653 cell line for hybridoma formation. This resulted in the generation
of the anti-PML 5D8 and the anti-RARA 9G4.16 antibodies.
Prototype immunobead assay
The here described and tested prototype immunobead assay for detection
of the PML–RARA fusion protein was essentially developed as described for
the BCR-ABL immunobead assay.22 Small adaptations were made in the
pretreatment and lysis reagents to improve the detection of the PML–
RARA fusion protein, which has a nuclear localization. This is in contrast to
the cytoplasmically expressed BCR-ABL fusion protein. In short, to inhibit
protease activity before cells lysis, intact cells were pretreated for 10min
on ice with the protease inhibitors 4-(2-aminoethyl) benzenesulfonyl
ﬂuoride hydrochloride, (AEBSF, Sigma, St Louis, MO, USA; 15mM AEBSF,
15ml of 1 M stock in phosphate-buffered saline (PBS)) and phenylmetha-
nesulfonyl ﬂuoride (PMSF, Sigma; 1mM, 5 ml of 200mM stock in ethanol) in
PBS at a concentration of 107 cells/ml. Next, cells were gently spun down
(5m at 500 g at 4 1C) and washed with 1ml of 5% fetal bovine serum in
PBS. After removal of the supernatant the cells were resuspended in BD
Pharmingen cell lysis buffer supplemented with 0.1% sodium dodecyl
sulfate, 2mM MgCl, 50U/ml of Benzonase, and the BD Baculogold protease
inhibitor cocktail solution diluted as described by the manufacturer (BD
Biosciences, San Jose´, CA, USA). After 15min incubation on ice, the lysate
was spun down at 14 000 r.p.m. (20 000 g) for 10min at 4 1C to remove cell
debris, and the supernatant was transferred to a fresh Eppendorf tube then
used in the cytometric bead assay.
In all, 50 ml of cell lysate was incubated with 50ml of bead-conjugated
anti-RARA (9G4.16) antibody (6000 beads) and 50 ml of PE-conjugated anti-
PML (5D8) antibody for 2 h at room temperature while being shaken.
Incubation was performed in either a 96-well ﬁlter plate (Multiscreen HTS
ﬁlter plates, MSBVN1250, Millipore, Tullagreen, Ireland) or in BD Falcon
12 75mm tubes. After incubation, the ﬁlter plate was washed twice with
200ml of BD CBA wash buffer and after the ﬁnal drain, the beads were
resuspended in the plate with 200ml of BD CBA wash buffer. The beads
incubated in BD Falcon 12 75mm tubes were washed one time by the
addition of 1ml of BD CBA wash buffer, and after pelleting the beads for
7min at 500 g at 4 1C, the beads were resuspended in 300ml of BD CBA
wash buffer. Analysis was performed on the results obtained from at least
1000 beads that were acquired on a BD FACS Canto II or BD LSR II ﬂow
cytometer using BD FACSDiva software, version 6.1 (BD Biosciences).
Instruments were setup according to the BD Cytometer Setup and Tracking
module and subsequently photo multipliers were adjusted using capture
beads according to the manufacturer’s recommendations, resulting in
mean ﬂuorescence intensity (MFI) values of 20 000, 40 000 and 100 for the
APC, APC-Cy7 and PE channels, respectively.
Speciﬁcity and sensitivity testing of the PML–RARA prototype
immunobead assay
The speciﬁcity of the PML–RARA prototype kit was conﬁrmed by the
analysis of cell lysates from leukemic cell lines with different types of fusion
proteins (see above).
The sensitivity of the PML–RARA prototype assay was determined by
analyzing serial dilutions of the NB4 cell line into both PBMC and WBC. All
analyses were performed in duplicate. MFI values detected in 100% PBMC
and 100% WBC were used as negative control values.
Testing of the PML–RARA prototype immunobead assay by the
EuroFlow Consortium
The PML–RARA prototype immunobead assay was tested in nine EuroFlow
laboratories on BM and/or PB samples of 163 leukemia patients at
initial diagnosis, including 46 APL patients (according to morphology
and/or immunophenotyping; 9 PB and 37 BM samples). Because of
the rarity of APL samples, a large fraction of the patient samples was
used from local cell banks. Only six of the 46 APL samples were fresh cell
samples. To facilitate the standardized collection of patient data with
accompanying results from PML–RARA testing, a Case Report Form was
developed for each sample with drop-down menus for all relevant
information. This case report form was electronically linked to a
corresponding Microsoft Excel ﬁle to guarantee transfer of data without
typing errors.
The PML–RARA prototype immunobead assay was performed according
to recommendations developed at BD Biosciences (see above). However,
in three laboratories without a refrigerated microcentrifuge, centrifugation
of lysates was performed at 20 000 g for 2min at room temperature instead
of 10min at 4 1C. Storage of the recovered lysates at 80 1C was allowed in
order to analyze multiple samples collectively for better comparison with
several positive and negative controls. Controls were provided by
Dynomics (lysates from 10% or 20% NB4 in PBMC as positive controls
and negative control lysates derived from PBMC).
PCR analysis of PML–RARA transcripts
PCR analysis of the different types of PML–RARA fusion transcripts was
performed with the standardized Europe Against Cancer (EAC) protocols
using TaqMan based real-time quantitative PCR (RQ-PCR; see Gabert et al.,
2003 for details).24 The ABL, GUS or B2M internal control genes for the real-
time quantitative-PCR studies were selected from the EAC study by Beillard
et al.25 According to the EAC guidelines, if too few control gene copies
were detected in patients without PML–RARA transcripts, those patient
samples were excluded from the study because of the low quality of
the RNA.25
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Statistical analysis
Statistical analyses using the Mann–Whitney U-test were performed to
compare mean MFI values between different PML–RARA positive samples,
between different PML break point types (bcr1, bcr2, bcr3) and between
different experimental conditions, for example, microcentrifugation at
room temperature for 2min versus at 4 oC for 10min and sample analysis
on the same day versus overnight. The relation between MFI values and
age of the samples was evaluated by Spearman’s rank correlation
coefﬁcient. A value of Po0.05 was regarded to be statistically signiﬁcant.
RESULTS
Testing of the PML–RARA immunobead assay on cell lines and a
small number of patient samples
Antibodies were developed against regions within PML and
RARA proteins, that are present in all described PML–RARA
fusion proteins (Figure 2). The anti-PML antibody 5D8 was raised
against exposed, nonhomologous amino-acid sequences. The
involved region is located upstream of the bcr’s (Figure 2a).
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Figure 2. Selection of the PML and RARA constructs for raising anti-PML and anti-RARA antibodies. (a) To increase the chance of making an
anti-PML antibody that worked in the immunobead assay, the PML immunogen had to meet specific criteria. The PML protein domains
encoded by exon 1–3 (upstream of all known break points) were analyzed with various web-based programs to identify exposed regions
(accessibility for the antibody), nonhomologous regions (no cross-reactivity with other human proteins) and antigenic determinants
(difference between human and mouse). Accordingly, the first PML domain (first 46 amino acids) before the ring-type zinc finger domain was
selected for cloning, protein expression, protein purification and subsequent immunization. The anti-PML antibody 5D8 was used in the
immunobead assay. (b) Using the same selection criteria, the C-terminal domain of RARA (last 70 amino acids) were used for cloning, protein
production and subsequent immunization. The anti-RARA antibody 9G4.16 was used in the immunobead assay.
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Using the same criteria, the anti-RARA antibody was raised
against sequences downstream of the RARA break point region
(Figure 2b). The selected anti-PML and anti-RARA antibodies were
tested for their suitability as bead-bound capture antibody and PE-
conjugated detection antibody. Best results were obtained when
the anti-RARA antibody was used as bead-bound capture antibody
and the anti-PML antibody as PE-conjugated detection antibody;
this conﬁguration was used in the prototype PML–RARA
immunobead assay (Figure 3).
The speciﬁcity of the assay was determined by testing leukemic
cell lines with t(15;17) or other translocations. Only the t(15;17)
positive NB4 cell line gave high PE-ﬂuorescent signals, whereas
the other cell lines tested exhibited low background signals
(Figure 4a). The sensitivity of the PML–RARA immunobead assay
was determined by dilution of the t(15;17) positive NB4 cell line in
both WBC and PBMC. The PML–RARA speciﬁc ﬂuorescent signal
was still detectable at concentrations as low as 10% of the NB4 cell
line (Figure 4b). This sensitivity is sufﬁcient, as PB and BM samples
of most APL patients at diagnosis contain more than 70% of
leukemic cells. Testing of a small series of APL patients with bcr1
or bcr3 PML–RARA variants showed that the immunobead assay
was positive in all APL patients and the results were independent
of the PML break point position (Figure 4c).
Testing of the PML–RARA prototype immunobead assay by the
EuroFlow Consortium
The PML–RARA prototype immunobead assay was distributed to
nine EuroFlow laboratories. A series of 163 leukemia patients was
evaluated, consisting of 112 AML patients (including 46 APL
patients), one chronic myeloid leukemia (CML) patient in
accelerated phase, 34 B-cell precursor acute lymphoblastic
leukemia (BCP-ALL) patients, and 16 T-ALL patients. For each
analysis of patient samples, both a positive and negative control
lysate were used to verify the proper performance of the
immunobead assay.
MFI values of the non-APL patient samples had a median value
of 114 (range 100–173) and a mean of 119 (s.d. 15.4). The MFI
values of the AML (non-APL) samples were slightly higher than the MFI
values of the B-cell precursor acute lymphoblastic leukemia samples
and T-ALL samples: mean of 121 (s.d. 18.3) versus 118 (s.d. 10.4)
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Figure 4. Detection of PML–RARA fusion protein in cell lines and
patient samples with the prototype PML–RARA immunobead assay.
(a) Cell lysates from cell lines with different translocations
expressing various fusion proteins: ME-1 with inv(16) expressing
CBFb-MYH11, MV4;11 with t(4;11) expressing MLL-AF4, K562 with
t(9;22) expressing BCR-ABL, 697 with t(1;19) expressing E2A-PBX1,
RCH-ACV with t(1;19) expressing E2A-PBX1, KASUMI-1 with t(8;21)
expressing AML1-ETO, REH with t(12;21) expressing TEL-AML1 did
not give a PE fluorescence signal in the PML–RARA immunobead
assay, whereas the cell line NB4 with t(15;17) expressing PML–RARA
(bcr1) gave a strong PE signal. (b) The PML–RARA positive NB4 cell
line was diluted into PBMC of a healthy individual and cell lysates
were prepared. The immunobead assay was carried out in triplicate
for every diluted sample. At a concentration of 10% NB4 cells a
signal-to-noise (s/n) ratio compared with the PBMC background of
2.7 was obtained. (c) The novel PML–RARA immunobead assay was
carried out on a series of cell lysates of AML patients without the
t(15;17) translocation (samples 1–5), APL patients with translocations
in the PML gene involving both the bcr1 and bcr3 region and of two
APL patients in which the break point region involved in the t(15;17)
translocation was not determined (samples 6–13), and of healthy
individuals (samples 14–19). Strong positive PE signals were only
obtained in the cell lysates of APL patients independent of the bcr
involved.
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and 113 (s.d. 8.7), respectively. The cutoff between negativity and
positivity was based on the MFI values of negative AML (non-APL)
samples, using 3-s.d. values, resulting in an MFI value of 176.
Consequently, a safe MFI cutoff value of 180 was deﬁned. All
tested PCR-negative samples and negative controls had an MFI
below this cutoff value. Based on the MFI cutoff value and the
values of the positive samples, several ranges of positive MFI
values were arbitrarily deﬁned to cluster the leukemias according
to the expression level of PML–RARA protein: high-level positivity:
MFI X1000; medium-level positivity: MFI X500, but o1000; low-
level positivity: MFI X180, but o500; negativity: MFI o180.
Full concordance (163/163; 100%) was observed between the
PML–RARA PCR results for fusion transcript detection and the
prototype PML–RARA immunobead results for fusion protein
detection (Tables 2 and 3 and Figure 5). A total of 46 APL patients
(22 children and 24 adults) were positive for PML–RARA with both
methods. All other 117 leukemia patients including 66 AML
patients (18 children and 48 adults), 1 CML patient (accelerated
phase), 34 BCP-ALL patients and 16 T-ALL patients, were PML–
RARA negative in both the assays (Table 2).
MFI values in patients with positivity for the PML–RARA
immunobead assay
The vast majority of PML–RARA positive patients had high MFI
values (65%) or medium MFI values (24%). Low MFI values (above
the cutoff value of MFI 180) were found in only 11% of the positive
patients (ﬁve cases): 192, 195, 273, 339 and 444 (Figure 5). The ﬁve
cases consisted of four adult patients and one child (Table 3). The
sample with the lowest MFI value of 192 concerned a PB sample
with only 37% leukemic cells, which was substantially less than in
most of the other APL samples (Figure 6). The samples with the
MFI values of 195 and 273 concerned 2 BM samples, which had a
long time lapse between sampling and processing of 3 days (65
and 60 h, respectively), which most likely has resulted in protein
degradation (see below). Finally, the samples with the MFI values
of 339 and 444 concerned a BM sample with 80% blast cells and a
PB sample with 42% blast cells, respectively.
Detection of PML–RARA proteins, derived from all three PML
break points
The immunobead assay was designed to detect all PML–RARA
fusion proteins that originate from the bcr1, bcr2 and bcr3 break
points in the PML genes. As summarized in Table 3, all three types
of break point regions in the PML gene were included in the
46 APL/AML cases with a positive PCR result for PML–RARA
transcripts: 21 cases with bcr1 (46%), 1 case with bcr2 (2%), and
24 cases with bcr3 (52%). This implies that indeed the anti-PML
and anti-RARA antibodies recognize epitopes that are sufﬁciently
upstream and downstream of the PML and RARA break point
cluster, respectively (Figure 5). The lower MFI values in APL
patients with bcr1 breaks as compared with APL patients with
bcr3 breaks just reached statistical signiﬁcance (P¼ 0.04 by Mann–
Whitney U-test; Figure 5). We speculated that this difference might
be caused by the fact that bcr1 PML–RARA proteins are 158 amino
acids longer than bcr3 PML–RARA proteins and consequently
might be more vulnerable for degradation. However, then we
realized that by coincidence the two cases with the lowest
percentages of leukemic cells (37 and 43%) belonged to the bcr1
Table 2. Results of PML–RARA detection by PCR and the immunobead assay performed in 163 patient samples
Newly diagnosed
patients
No. of
patients
PML–RARA
mRNA positive
PML–RARA immunobead assay
Positive MFI positive MFI negative Mean 3-s.d.
Median Range Median Range
APL (AML-M3) 46 46 46 1514 192–32.160 NA NA NA NA
AML, non-APL 66 0 0 NA NA 114 100–173 121 55
CML accelerated phase 1 0 0 NA NA 131 NA NA NA
BCP-ALL 34 0 0 NA NA 115 106–151 118 31
T-ALL 16 0 0 NA NA 113 113–130 113 26
Total 163 46 46 1514 192–32.160 114 100–173 119 46
Abbreviations: AML-M3, acute myeloid leukemia type M3; APL, acute promyelocytic leukemia; BCP-ALL, B-cell precursor acute lymphoblastic leukemia; CML,
chronic myeloid leukemia; NA, not applicable.
Table 3. Results of PML–RARA detection by PCR and the novel immunobead assay in AML patients according to age, PML break point and MFI value
Leukemia type No. of samples PML–RARA mRNA positivity MFI of PML–RARA protein positivity
bcr1 bcr2 bcr3 Low (180–500) Medium (500–1000) High (41000)
APL
Childhood 22 11 1 10 1 7 14
Adult 24 10 0 14 4 4 16
Other AML
Childhood 18 0 0 0 0 0 0
Adult 48 0 0 0 0 0 0
Total 112 21 1 24 5 11 30
(46%) (2%) (52%) (11%) (24%) (65%)
Abbreviations: AML, acute myeloid leukemia; APL, acute promyelocytic leukemia.
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PML–RARA patient group, both being blood samples. In fact, 5 of
the 6 cases with less than 70% leukemic cells belonged to the bcr1
PML–RARA group (Figure 6). So, the seemingly lower MFI values of
the APL patients with bcr1 breaks is merely related to lower
percentages of leukemic cells in the tested samples. Interestingly,
if the Mann–Whitney U-test was performed for BM samples only
(17 bcr1 and 18 bcr3), no signiﬁcant difference was found
between the MFI values of patient samples with bcr1 versus bcr3
breaks (P¼ 0.06).
Relation between PML–RARA protein level and percentage of
leukemic cells
To evaluate whether differences in MFI levels between leukemias
might be related to the percentage of leukemic cells present in
the tested samples, MFI values were plotted against APL cell
percentages (Figure 6). MFI values from APL patients with bcr1
breaks seemed to have some correlation with the percentage of
leukemic cells (Spearman’s rho coefﬁcient ¼ 0.45; P¼ 0.048),
whereas no signiﬁcant relation was observed for patients with
bcr3 breaks (Spearman’s rho coefﬁcient¼  0.21; P¼ 0.32). It
should be remarked that the percentages of leukemic cells in the
bcr1 group varied over a broader range (37–99%) as compared
with the bcr3 group (68–97%) (Figure 6).
Microcentrifugation of cell lysates and temperature
The 46 PML–RARA positive patient samples were evaluated for
effects resulting from temperature differences during micro-
centrifugation. A total of 27 cases were in the 10min 4 1C group
and had a median MFI value of 1460 and a mean of 3042 (s.d.
6098). The high mean value and the high s.d. value appeared to
be caused by the fact that this group contained 4 of the 5 low MFI
values and the single very high MFI value of 32 160. The other 19
cases were in the 2min room temperature group with a median
MFI value of 1697 and a mean value of 2108 (s.d. 1769). The
Mann–Whitney U-test did not show a signiﬁcant difference
(P¼ 0.7). Consequently, the temperature of the microcentrifuga-
tion step does not seem to inﬂuence the results of the PML–RARA
immunobead assay.
No effect of time lapse between sampling and processing of the
patient material within the ﬁrst 36 h
To understand whether longer transportation and/or processing
times might have a negative impact on the quality and reliability
of the PML–RARA immunobead assay, the EuroFlow laboratories
were asked to make a fair estimate of the time lapse between
sampling and processing of the patient material. These assessed
and estimated time lapses were reported in the case report forms.
The time lapse was reported in 30 of the 46 PML–RARA positive
cases: 10 cases were processed on the same day (within 8 h), 17
cases on the next day (18–36 h), and 3 cases were processed on
the third day or later (448 h). Comparison of the MFI values did
not show a clear decrease between cases processed within 8 h
(same day) and 18–36 h (next day) (P¼ 0.88 by Mann–Whitney
U-test; Figure 7). We cannot draw conclusions from the three
samples processed on the third day or later (448 h), other than
the fact that 2 of the 3 samples had a very low MFI value (MFI: 195
and 273).
These results indicate that processing within 36 h does not
harm the performance of the PML–RARA prototype immunobead
assay. The results of patient samples processed after 36 h (after 2
days) should be analyzed with caution.
Paired blood and BM samples
Nine paired fresh BM and PB samples were analyzed, six of which
were derived from APL patients at the time of diagnosis and three
from non-APL patients. The results of the six paired PB–BM APL
samples showed that the intra-individual PML–RARA protein
expression in leukemic cells from BM and PB is fully comparable
(Figure 8).
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Figure 6. Level of PML–RARA fusion protein in relation to
percentage of leukemic cells. No significant relationship was found
between MFI values and percentages of leukemic cells. MFI values of
the APL patients with bcr1 breaks had some correlation with
percentage of leukemic cells (Spearman’s rho coefficient 0.45;
P¼ 0.048), whereas such correlation was not observed for patients
with bcr3 breaks (Spearman’s rho coefficient  0.21; P¼ 0.32).
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Figure 5. Results of the EuroFlow testing of the prototype PML–
RARA immunobead assay. MFI values were plotted per patient
group. The results of the RQ-PCR analyses are indicated with
symbols (bcr1, bcr2, bcr3 and negative). The lower MFI values in APL
patients with bcr1 breaks as compared with APL patients with bcr3
breaks reached statistical significance (Mann–Whitney U-test:
P¼ 0.04), if all samples (PB and BM) were analyzed. As PB samples
tend to have lower percentages of leukemic cells (particularly in
bcr1 cases), we repeated the Mann–Whitney U-test for the BM
samples only (17 bcr1 and 18 bcr3), which showed no significant
difference between bcr1 and bcr3 cases (P¼ 0.06). Further details
about the PML–RARA positive samples are given in Figures 6–8.
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DISCUSSION
The PML–RARA fusion protein is the hallmark of APL and is present
in 92% of APL patients with the classical t(15;17) translocation and
in 5% of APL patients with nonclassical genetic aberrations such as
insertions or complex chromosomal aberrations. PML–RARA
positive APL patients often present with coagulopathy and
without the right treatment, 40% of the patients develop
pulmonary and cerebral hemorrhages, which can be lethal.
Therefore, APL is a medical emergency, and the diagnosis of
PML–RARA positive APL should be triaged fast enough to enable
patients to enter a correct treatment protocol as soon as possible.
In this study, we developed a simple and fast ﬂow cytometric
immunobead assay for the detection of PML–RARA fusion proteins
based on the same principle as described for the BCR-ABL protein
immunobead assay.22 For the detection of PML–RARA fusion
proteins in cell lysates, antibodies were raised against the
N-terminal domain of PML, upstream of the break point region
BCR3 and present in all known PML–RARA fusion proteins, and
against the C-terminal domain of RARA (downstream of the RARA
break points in intron 2). The antibodies were either bead-coupled
or labeled with a ﬂuorochrome. PML–RARA proteins were
detected in the immunobead assay using a bead-bound capture
antibody against one side of the fusion protein (anti-RARA) and a
ﬂuorochrome-conjugated detection antibody against the other
side of the fusion protein (anti-PML).
The prototype immunobead assay appeared to be speciﬁc for
the detection of the PML–RARA fusion proteins as a positive signal
was obtained only when the epitopes of both the anti-PML and
anti-RARA antibodies were present in a protein lysate. No
background signals were obtained in cell lines with wild-type
proteins or other fusion proteins. The sensitivity of the PML–RARA
prototype immunobead assay was at least 10% for the NB4 cell
line. This sensitivity should be sufﬁcient to successfully identify all
APL patients with a PML–RARA fusion gene, as PB and BM samples
of most APL patients at diagnosis contain more than 70% of
leukemic cells; this was also the case in 87% of our APL patient
samples. Nevertheless, it is recommended that the assay will be
conducted on BM samples, as in APL patients with pancytopenia
very few leukemic cells might be present in PB samples.15
The suitability of the novel immunobead assay was further shown
by detection of PML–RARA fusion proteins originating from both
the bcr1 (downstream) and bcr3 (upstream) break points in the
PML gene.
After further optimization, the prototype immunobead assay
was distributed for large-scale testing to nine diagnostic
laboratories enrolled in the EuroFlow consortium. The results
obtained with the PML–RARA immunobead assay were fully
concordant with the PCR results in a series of 163 patient samples
including 46 APL patients, 66 non-APL AML patients, one CML
patient in accelerated phase of the disease, 34 BCP-ALL patients
and 16 T-ALL patients.
In the series of APL patients included in this study, the adult and
childhood cases were equally represented and they showed
comparable levels of PML–RARA fusion protein. The detection of
PML–RARA fusion proteins in the 46 APL cases studied at
diagnosis was independent of the type of PML break point
(bcr1, bcr2, or bcr3). This implies that the location of the epitopes
used for generation of the anti-PML and anti-RARA antibodies
were chosen sufﬁciently upstream and downstream of the known
break point clusters. As the bead assay is designed to be
independent of the PML break points, PCR analysis might be
needed at a later stage for identiﬁcation of the PML break point
variant in order to use the appropriate PCR primers for disease
monitoring in individual patients.3,24,26
Analysis of the MFI levels detected with the prototype
immunobead assay did not show a clear correlation with the
percentages of leukemic cells present in the samples. This could
imply that different APL cases may express different levels of
PML–RARA fusion proteins. This explanation is supported by the
evaluation of PML–RARA expression levels in paired BM and PB
samples, which showed clear patient-to-patient differences
between the six APL patients analyzed. In contrast, comparable
PML–RARA expression levels were detected within in the paired
BM and PB samples of the same patient.
Processing of leukemia samples in the same day, or the ﬁrst day
after sampling gave comparable results. However, it is not clear
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Figure 7. Level of PML–RARA fusion protein expression versus time
lapse in sample processing.Comparison of the MFI values did not
show a clear decrease between cases processed within 8 h (same
day), and 18–36 h (next day) (Mann–Whitney U-test: P¼ 0.88). Three
samples were processed after more than 2 days; two of them had
low MFI values.
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Figure 8. Comparison of PML–RARA fusion protein expression levels
between paired BM and PB samples of nine acute leukemias at
diagnosis. In all paired BM and PB samples of the same patient, fully
comparable MFI values were observed. Remarkably, the MFI values
of the BM and PB levels in the six APL cases showed a wide variation
between patients, but were comparable in each individual patient.
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from this study whether a longer time lapse between sampling
and processing would lead to suboptimal results (too few samples
tested), but it is advised to keep the time lapse between sampling
and processing within 36 h. As it is not known whether protein
integrity is affected during transportation and the time lapse
between sampling and processing, it would be advantageous to
supplement the immunobead assay with an internal control for
the assessment of protein quality in the cell lysates, as also
proposed for the previously reported study performed with the
BCR-ABL protein kit.22
We conclude that the ﬂow cytometric immunobead assay is a
very powerful diagnostic tool for detection of PML–RARA fusion
proteins in leukemic cells. Because of the severe course of APL, a
clinical assay with high speciﬁcity and sensitivity is critically
needed to positively identify APL patients within a total group of
AML patients.15,16 Comparable to the BCR-ABL immunobead assay
described previously, the PML–RARA immunobead assay also
exhibits several obvious advantages over classical PCR and FISH
techniques. The immunobead assay is independent of the break
point position in the fusion gene, there is no need for special
laboratory facilities, the assay requires no specialized equipment
other than a standard ﬂow cytometer, the results can be obtained
in approximately 4 h, and the assay can be run in parallel to
routine immunophenotyping without the need for extra tech-
nician time. It should be noted that the sensitivity of the current
prototype PML–RARA immunobead assay is at least 10%, which is
less sensitive than PCR and also slightly less sensitive than FISH,
but sufﬁciently sensitive for the formal diagnosis of acute
leukemia, if BM samples are analyzed with sufﬁciently high
percentages of leukemic cells. Consequently, the novel PML–RARA
immunobead assay will contribute to an earlier diagnosis of APL
and thereby will enable clinicians to start speciﬁc treatment as
soon as possible. Use of the novel PML–RARA immunobead assay
hopefully will prevent the patients from developing any life-
threatening bleeding problems because of early stage treatment.
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